Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjögren's syndrome

Clin Exp Rheumatol. 2017 Jul-Aug;35(4):719-720. Epub 2017 Mar 8.

Authors

Luca Quartuccio¹, Clio P Mavragani², Adrianos Nezos², Saviana Gandolfo³, Athanasios G Tzioufas², Salvatore De Vita³

Affiliations

¹ Department of Biological and Medical Sciences, Rheumatology Clinic, University of Udine, Italy. [email protected].
² Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Greece.
³ Department of Biological and Medical Sciences, Rheumatology Clinic, University of Udine, Italy.

PMID: 28281461

No abstract available

Publication types

Letter

MeSH terms

Adaptor Proteins, Signal Transducing
Antibodies, Monoclonal, Humanized / therapeutic use*
Antigens / genetics
Carrier Proteins / genetics
Chemokine CXCL9 / genetics
Cytoskeletal Proteins / genetics
Female
GTP-Binding Proteins / genetics
Humans
Immunoglobulin A / immunology
Immunoglobulin G / immunology
Immunoglobulin M / immunology
Immunosuppressive Agents / therapeutic use*
Interferon Type I / immunology
Interferon-gamma / immunology
Middle Aged
Myxovirus Resistance Proteins / genetics
RNA-Binding Proteins
Real-Time Polymerase Chain Reaction
Rheumatoid Factor / immunology
Sjogren's Syndrome / drug therapy*
Sjogren's Syndrome / immunology
Treatment Outcome

Substances

Adaptor Proteins, Signal Transducing
Antibodies, Monoclonal, Humanized
Antigens
CXCL9 protein, human
Carrier Proteins
Chemokine CXCL9
Cytoskeletal Proteins
GBP1 protein, human
IFI44 protein, human
IFIT1 protein, human
Immunoglobulin A
Immunoglobulin G
Immunoglobulin M
Immunosuppressive Agents
Interferon Type I
MX1 protein, human
Myxovirus Resistance Proteins
RNA-Binding Proteins
belimumab
Interferon-gamma
Rheumatoid Factor
GTP-Binding Proteins